Alteplase for Treating Acute Ischaemic Stroke (TA264 [Review of TA122])

Technology Appraisal Guidance No. 264

Source: National Institute for Health and Care Excellence

1. Guidance

This guidance replaces NICE technology appraisal guidance 122 (published in June 2007). For details see About this guidance.

1.1  Alteplase is recommended within its marketing authorisation for treating acute ischaemic stroke in adults if:

  • treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and
  • intracranial haemorrhage has been excluded by appropriate imaging techniques.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA.

Alteplase for treating acute ischaemic stroke (review of Technology Appraisal Guidance 122)
Issue Date: September 2012

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in